Want to see HK:1873 full AI Analyst Report?
Viva Biotech Holdings (1873) Stock Statistics & Valuation Metrics
Total Valuation
Viva Biotech Holdings has a market cap or net worth of HKD 2.60B. The enterprise value is HKD 2.50B.
- Market Cap
- HKD 2.60B
- Enterprise Value
- HKD 2.50B
Share Statistics
Viva Biotech Holdings has 2,093,553,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 2,093,553,500
- Owned by Insiders
- ―
- Owned by Institutions
- 0.01%
Financial Efficiency
Viva Biotech Holdings’s return on equity (ROE) is 0.05 and return on invested capital (ROIC) is 2.42%.
- Return on Equity (ROE)
- 0.05
- Return on Assets (ROA)
- 0.03
- Return on Invested Capital (ROIC)
- 2.42%
- Return on Capital Employed (ROCE)
- 0.03
- Revenue Per Employee
- 781.49K
- Profits Per Employee
- 99.30K
- Employee Count
- 2,213
- Asset Turnover
- 0.24
- Inventory Turnover
- 3.20
Valuation Ratios
The current PE Ratio of Viva Biotech Holdings is 12.89. Viva Biotech Holdings’s PEG ratio is 14.99.
- PE Ratio
- 12.89
- PS Ratio
- 1.16
- PB Ratio
- 0.56
- Price to FCF
- 7.68
- Price to Operating Cash Flow
- 5.21
- PEG Ratio
- 14.99
Income Statement
In the last 12 months, Viva Biotech Holdings had revenue of 1.73B and earned 219.76M in profits. Earnings per share was 0.09.
- Revenue
- 1.73B
- Gross Profit
- 655.56M
- Operating Income
- 193.25M
- Pretax Income
- 318.00M
- Net Income
- 219.76M
- EBITDA
- 404.30M
- Earnings Per Share (EPS)
- 0.09
Cash Flow
In the last 12 months, operating cash flow was 427.35M and capital expenditures -142.75M, giving a free cash flow of 284.60M billion.
- Operating Cash Flow
- 427.35M
- Free Cash Flow
- 284.60M
- Free Cash Flow per Share
- 0.14
Dividends & Yields
Viva Biotech Holdings pays an annual dividend of HKD 0.01, resulting in a dividend yield of ―
- Dividend Per Share
- HKD 0.01
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 13.02%
- Earnings Yield
- 7.94%
Stock Price Statistics
- Beta
- 1.93
- 52-Week Price Change
- -47.03%
- 50-Day Moving Average
- 1.42
- 200-Day Moving Average
- 1.63
- Relative Strength Index (RSI)
- 40.47
- Average Volume (3m)
- 5.75M
Important Dates
Viva Biotech Holdings upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 26, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- Jun 16, 2021
Financial Position
Viva Biotech Holdings as a current ratio of 1.50, with Debt / Equity ratio of 33.29%
- Current Ratio
- 1.50
- Quick Ratio
- 1.26
- Debt to Market Cap
- 0.34
- Net Debt to EBITDA
- 0.55
- Interest Coverage Ratio
- 5.29
Taxes
In the past 12 months, Viva Biotech Holdings has paid 48.73M in taxes.
- Income Tax
- 48.73M
- Effective Tax Rate
- 0.15
Enterprise Valuation
Viva Biotech Holdings EV to EBITDA ratio is 5.22, with an EV/FCF ratio of 7.20.
- EV to Sales
- 1.08
- EV to EBITDA
- 5.22
- EV to Free Cash Flow
- 7.20
- EV to Operating Cash Flow
- 4.79
Balance Sheet
Viva Biotech Holdings has HKD 1.06B in cash and marketable securities with HKD 897.96M in debt, giving a net cash position of HKD 158.46M billion.
- Cash & Marketable Securities
- HKD 1.06B
- Total Debt
- HKD 897.96M
- Net Cash
- HKD 158.46M
- Net Cash Per Share
- HKD 0.08
- Tangible Book Value Per Share
- HKD 0.73
Margins
Gross margin is 34.55%, with operating margin of 10.05%, and net profit margin of 9.36%.
- Gross Margin
- 34.55%
- Operating Margin
- 10.05%
- Pretax Margin
- 13.46%
- Net Profit Margin
- 9.36%
- EBITDA Margin
- 20.78%
- EBIT Margin
- 10.05%
Analyst Forecast
The average price target for Viva Biotech Holdings is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 7.38%
- EPS Growth Forecast
- 7.90%
Scores
- Smart Score
- 3
- AI Score
- 64